BriaCell Adds Penn Medicine's Abramson Cancer Center as Clinical Site in Pivotal Phase 3 Breast Cancer Study

PHILADELPHIA and VANCOUVER, British Columbia, May 13, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care is pleased to announce the addition of Penn Medicine's Abramson Cancer Center, an internationally recognized cancer center, as a clinical trial site in BriaCell's ongoing pivotal Phase 3 clinical study (Bria-ABC).